Fact-check: TCOYD's Mounjaro versus Ozempic showdown

What the video covers

Dr. Steven Edelman and Dr. Jeremy Pettus award a sticker per category: A1c, weight, side effects, kidney protection, heart protection, sleep apnoea, ease of dosing and use in type 1 diabetes. They open with three caveats, that the drugs act on different receptors, that the same molecules carry different brand names for diabetes and for weight, and that semaglutide has been around longer and has more data.

What it gets right

The category calls follow the evidence. Tirzepatide wins A1c and weight on the strength of SURPASS-2, in which all three tirzepatide doses beat semaglutide 1 mg (PubMed 34170647), and the presenters say the doses were not equivalent, which is the key caveat. Semaglutide wins kidney protection because of FLOW, where it reduced the kidney composite by 24 percent in people with type 2 diabetes and chronic kidney disease (PubMed 38785209), and heart protection because of SUSTAIN-6 (PubMed 27633186) and SELECT; at recording, tirzepatide's cardiovascular outcomes trial had not reported. Tirzepatide wins sleep apnoea on SURMOUNT-OSA and its December 2024 indication (PubMed 38912654). The closing message, that the drugs are more alike than different and must be continued to keep the benefit, matches the withdrawal trials.

The type 1 diabetes section is candid: both drugs work physiologically, neither is approved in type 1, and the companies had not run the trials.

What it leaves out or overstates

Two pieces of practical advice should not be followed without a prescriber's explicit instruction. First, one presenter describes counting pen "clicks" to take a dose between the labelled strengths on an Ozempic pen. The Ozempic label instructs users to dial the dose to the marked strength and states that the dose counter, not clicks, confirms the dose; a partial dial is off-label improvisation and the device is not designed to deliver it accurately. Second, a presenter suggests that a person with type 1 diabetes seeking Wegovy or Zepbound should "never mention the word diabetes on the form". Omitting a diagnosis from a medical or insurance form is not something we can endorse, whatever the intent.

The side-effect category is thin. Both presenters say tolerability is similar with slow titration, which is broadly true, but neither gives the label rates: nausea occurred in 44 percent of the Wegovy 2.4 mg group in its pooled trials and in 25 to 29 percent across Zepbound doses, each against placebo rates in the high single digits to low teens. The costs and coverage barriers that decide most real prescriptions are mentioned only as "covered by your insurance".

Where to go next

For a side-by-side of every agent from label and trial data, use the comparison table on GLP-1s Explained. The Semaglutide Hub and Tirzepatide Hub each have missed-dose helpers built on the label rules. FormBlends offers compounded versions of both molecules at formblends.com; compounded products are not FDA approved, are not interchangeable with Ozempic, Wegovy, Mounjaro or Zepbound, and none of the trials above studied them.